TITLE

THE DRUG QUALITY AND SECURITY ACT OF 2013: COMPOUNDING CONSISTENTLY

AUTHOR(S)
HAEYOUNG KIM, STELLA
PUB. DATE
July 2017
SOURCE
Journal of Health Care Law & Policy;2017, Vol. 19 Issue 2, p299
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers insight to the U.S. Drug Quality and Security Act. Topics discussed include history of drug regulations in the country; standards made by the U.S. Food and Drug Administration safe production and distribution of customized medicine for safe patient use; and Wedgewood Village Pharmacy, Inc. v. United States court case on the same.
ACCESSION #
126275156

 

Related Articles

  • The Food and Drug Administration Amendments Act and Postmarketing Commitments. Fain, Kevin; Daubresse, Matthew; Alexander, G. Caleb // JAMA: Journal of the American Medical Association;7/10/2013, Vol. 310 Issue 2, p202 

    The article focuses on a study which examined the changes associated with post-marketing studies that are required for a prescription drug's approval and adherence by the U.S. Food and Drug Administration (FDA) as per the Food and Drug Administration Amendments Act (FDAAA) of 2007. It further...

  • 'What if I were your sister?'. Goodin, Susan // Pharmacy Today;Nov2011, Vol. 17 Issue 11, p2 

    The article offers the author's insights on issues concerning drug shortages in the U.S. The author says that the U.S. Food and Drug Administration (FDA) and congressional hearings in September 2011 focused on understanding the causes and impacts of the shortages. She states that the pharmacy...

  • Move to allow purchase of Canadian drugs rejected.  // Modern Healthcare;10/24/2011, Vol. 41 Issue 43, p4 

    This article reports on the U.S. Senate's disapproval of an amendment to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.

  • Helping to shape drug shortage provisions in FDA user fee legislation. Keating, Armand // MLO: Medical Laboratory Observer;Oct2012, Vol. 44 Issue 10, p38 

    The article focuses on the U.S. FDA Safety and Innovation Act of 2012 which reauthorizes the FDA's user fee programs for five years and creating user fee programs for generic and biologic drugs. The law also addresses the problem of drug shortages which have had particularly devastating effects...

  • Laws fail to slow gray market. Lee, Jaimy // Modern Healthcare;10/3/2011, Vol. 41 Issue 40, p14 

    The article expresses the concern of pharmacists and health providers regarding the short supply of drugs sold by secondary distributors. It says that there were 210 cases of drug shortages reported as of September 26, 2011 and that drugs purchased from the gray market were often priced 20 times...

  • Evaluating Hepatitis B Virus Reactivation During Solid Tumor Chemotherapy: Evidence to Guide Pretreatment Hepatitis B Screening and Prophylaxis. Lo Re III, Vincent; Schuster, Mindy; Lo Re, Vincent 3rd // Annals of Internal Medicine;1/5/2016, Vol. 164 Issue 1, p64 

    The author discusses on study on risk for reactivation of hepatitis B virus (HBV) infection with chemotherapy for solid tumors. He states that the U.S. Food and Drug Administration has issued drug safety communication regulation urging health care providers to screen patients for HBV infection...

  • Metrics Sought to Ensure Drug Quality. Wechsler, Jill // BioPharm International;Jan2014, Vol. 27 Issue 1, p12 

    The article discusses the effort of the officials of the U.S. Food & Drug Administration (FDA) to establish a valid basis for ensuring that drugs and biotechnology therapies adhere to high quality standards through the product life cycle. Particular focus is given to the work of regulators with...

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics